PL2575793T3 - N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę - Google Patents

N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę

Info

Publication number
PL2575793T3
PL2575793T3 PL11726946T PL11726946T PL2575793T3 PL 2575793 T3 PL2575793 T3 PL 2575793T3 PL 11726946 T PL11726946 T PL 11726946T PL 11726946 T PL11726946 T PL 11726946T PL 2575793 T3 PL2575793 T3 PL 2575793T3
Authority
PL
Poland
Prior art keywords
neuroprotective
leucine
acetyl
retinoprotective
medicament
Prior art date
Application number
PL11726946T
Other languages
English (en)
Inventor
Raouf Rekik
Original Assignee
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raouf Rekik filed Critical Raouf Rekik
Publication of PL2575793T3 publication Critical patent/PL2575793T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL11726946T 2010-06-03 2011-05-06 N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę PL2575793T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TN2010000251A TN2010000251A1 (fr) 2010-06-03 2010-06-03 N-acetyl-dl-leucine medicament neuro et retino protecteur
PCT/IB2011/000965 WO2011151685A1 (en) 2010-06-03 2011-05-06 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
EP11726946.4A EP2575793B1 (en) 2010-06-03 2011-05-06 N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament

Publications (1)

Publication Number Publication Date
PL2575793T3 true PL2575793T3 (pl) 2019-04-30

Family

ID=54695902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11726946T PL2575793T3 (pl) 2010-06-03 2011-05-06 N-acetylo-dl-leucyna, środek neuroprotekcyjny i chroniący siatkówkę

Country Status (12)

Country Link
US (1) US9155719B2 (pl)
EP (1) EP2575793B1 (pl)
JP (1) JP5959507B2 (pl)
CN (1) CN103079550A (pl)
AU (1) AU2011259997B2 (pl)
CA (1) CA2801145C (pl)
ES (1) ES2686295T3 (pl)
PL (1) PL2575793T3 (pl)
RU (1) RU2598339C2 (pl)
TN (1) TN2010000251A1 (pl)
WO (1) WO2011151685A1 (pl)
ZA (1) ZA201209595B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658461C2 (ru) 2012-06-29 2018-06-21 Рауф РЕКИК Ингибиторы ангиотензинпревращающего фермента для лечения нейропатии зрительного нерва или врождённой атрофии зрительного нерва
JP6764233B2 (ja) * 2015-02-10 2020-09-30 国立大学法人京都大学 眼疾患処置薬
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
JP7393943B2 (ja) * 2016-08-11 2023-12-07 イントラバイオ リミティド リソソーム蓄積障害に関する医薬組成物及び使用
SG11201901063SA (en) * 2016-08-11 2019-03-28 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
KR102549684B1 (ko) * 2017-10-18 2023-06-29 인트라바이오 리미티드 신경퇴행성 질병에 대한 치료제
US11660279B2 (en) 2018-02-15 2023-05-30 Intrabio Limited Therapeutic agents for treating restless leg syndrome
US20220062209A1 (en) 2018-12-18 2022-03-03 Santen Pharmaceutical Co., Ltd. Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
AU2020231189A1 (en) * 2019-03-02 2021-09-30 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20240100077A1 (en) * 2021-01-23 2024-03-28 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255722A (ja) * 1984-05-30 1985-12-17 Otsuka Pharmaceut Factory Inc 糖尿病用アミノ酸輸液
US4837219A (en) 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
DE3811177A1 (de) * 1988-03-31 1989-10-19 Ernst Hajek Verwendung von (alpha)-amino-isocapronsaeure (leucin) als wirkstoff zur bekaempfung der hiv-erkrankung aids
JPH0368514A (ja) 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
DE4243362A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Mittel zur Behandlung von Hauttrockenheit, des Neuroendokriniums und Immunsystems
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
JPH10323183A (ja) * 1997-03-25 1998-12-08 Otsuka Pharmaceut Factory Inc 細胞保護液
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
JP3341769B1 (ja) * 2002-01-25 2002-11-05 味の素株式会社 分岐鎖アミノ酸含有チュアブル剤
US7795203B2 (en) * 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
KR20110120981A (ko) * 2002-12-26 2011-11-04 아지노모토 가부시키가이샤 간암 발생 및 진행 억제제
JP4528925B2 (ja) * 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
WO2005023368A1 (en) * 2003-09-04 2005-03-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
JP2008024675A (ja) * 2006-07-25 2008-02-07 Kowa Co 内服液剤組成物
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2098124A1 (en) * 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate gel
US20110318424A1 (en) * 2008-12-03 2011-12-29 President And Fellows Of Harvard College METHODS FOR PROLONGING VIABILITY OF CONE CELLS USING MODULATORS OF THE MAMMALIAN TARGET OF RAPAMYCINE (mTOR)
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs

Also Published As

Publication number Publication date
TN2010000251A1 (fr) 2011-11-11
ES2686295T3 (es) 2018-10-17
JP5959507B2 (ja) 2016-08-02
AU2011259997A1 (en) 2013-01-24
AU2011259997A8 (en) 2013-05-02
AU2011259997A2 (en) 2013-01-31
RU2012151575A (ru) 2014-07-20
WO2011151685A8 (en) 2013-01-10
EP2575793B1 (en) 2018-06-06
AU2011259997A9 (en) 2013-05-02
US9155719B2 (en) 2015-10-13
AU2011259997B2 (en) 2016-05-05
US20130142888A1 (en) 2013-06-06
RU2598339C2 (ru) 2016-09-20
JP2013527222A (ja) 2013-06-27
CA2801145A1 (en) 2011-12-08
ZA201209595B (en) 2014-03-26
CA2801145C (en) 2019-08-06
EP2575793A1 (en) 2013-04-10
CN103079550A (zh) 2013-05-01
WO2011151685A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
ZA201209595B (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
GB201012175D0 (en) Procedure and mechanisms
GB201010193D0 (en) Medicinal use
HK1179157A1 (en) Radioimmunoconjugates and uses thereof
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
PL2523646T3 (pl) Smoczek z tarczką oraz tarczka
ZA201304026B (en) Folic acid-ramipril combination:cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2515903A4 (en) COMPOUNDS, PREPARATION AND USES THEREOF
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
EP2564852A4 (en) MEDICAMENT TREATING CEREBRAL TUMORS
HK1180988A1 (zh) 尤其是用於注射器及類似物的功能性提高的保護裝置
PL2536400T3 (pl) Lek zawierający miramistin
HK1162526A1 (en) Glp-1 derivatives and uses thereof glp-1
AP2011006033A0 (en) Simalikalactone E and use thereof as a medicament.
IL220859A0 (en) Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application
EP2621490A4 (en) PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
GB0902875D0 (en) Medicaments,uses and methods
GB201001317D0 (en) Medicament
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB0903145D0 (en) Medicaments uses and methods
GB201002451D0 (en) Pharmaceutical comopitions and devices